Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525240 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTL3MBTL1WDR5HPGD | |
| SCHEMBL5525241 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTL3MBTL1WDR5HPGD | |
| SCHEMBL6484484 | 0.93 | MAPT (0.44) | SMN1; SMN2MAPTL3MBTL1WDR5 | |
| SCHEMBL3588721 | 0.87 | KDM1A (0.47) | — | |
| SCHEMBL2171729 | 0.87 | KDM1A (0.47) | — | |
| SCHEMBL2171728 | 0.87 | KDM1A (0.47) | — | |
| SCHEMBL11488255 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTL3MBTL1WDR5HPGD | |
| SCHEMBL11878664 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTL3MBTL1WDR5HPGD | |
| SCHEMBL11881044 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTL3MBTL1WDR5HPGD | |
| SCHEMBL6484429 | 0.83 | HSD17B2 (0.46) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043035-A1 | Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-02-22 | — | — | US | disclosed |
| US-20070043035-A1 | Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-02-22 | — | — | US | disclosed |
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043035-A1 | Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, LIPC | SMN1; SMN2 4582/4885MAPT 4179/4885L3MBTL1 4808/4885 |
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | SMN1; SMN2 3127/4885MAPT 3845/4885L3MBTL1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.